Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT138806252471N1
IRCT138806252471N1
Completed
未知

Comparison of immunogenicity and short term reactogenicity of a local and a WHO approved commercial MMR vaccines in Iranian children and infants

Deputy of food and drugs, Ministry of health and Medical Education0 sites720 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMMR.Need for immunization against measles-mumps-rubella [MMR]

Overview

Phase
未知
Intervention
Not specified
Conditions
MMR.
Sponsor
Deputy of food and drugs, Ministry of health and Medical Education
Enrollment
720
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Deputy of food and drugs, Ministry of health and Medical Education

Eligibility Criteria

Inclusion Criteria

  • •Healthy children
  • •Exclusion criteria: Incomplete vaccination card, immunodeficiency disease, severe asthma and allergy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Comparition of immunity and reaction of bOPV vaccine and tOPV vaccine in routine immunization schedule, with or without IPV vaccine administration at DTP3 vaccine contact: A controlled trial
CTRI/2013/06/003722World health Organization900
Completed
Not Applicable
Comparative evaluation of immunogenicity and reactogenicity of monovalent type 2 and 3 oral poliovirus vaccines (mOPV 2 and mOPV3) versus trivalent oral poliovirus vaccine (tOPV), and bivalent oral poliovirus vaccine (bOPV) versus monovalent types 1 and 3 oral poliovirus vaccines, respectively: a randomised double-blind trial
ISRCTN64725429Panacea Biotec Limited (India)900
Completed
Phase 3
Comparison of immunogenicity and reactogenicity of bivalent oral poliovirus vaccine versus pre-qualified bivalent oral poliovirus vaccine: a randomized double-blind trial
CTRI/2010/091/000591Panacea Biotec Limited272
Active, not recruiting
Not Applicable
ong Term Follow-up (LTFU) study 16-20 yrs after vaccine dose of hepatitis b with/without Hepatitis B immunoglobulin (HBIG) in newborns to Hepatitis B envelope antigen positive (HBeAg+) mothers.Vaccination of healthy newborns of HBsAg+ and/or HBeAg+ mothers against Hepatitis.Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2011-004879-36-Outside-EU/EEAGlaxoSmithKline Biologicals69
Completed
Not Applicable
Research to improve economical anti-rabies treatment
ISRCTN30087513niversity of Oxford (UK)220